BioSpace News Archive

Drug Development

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, announced top-line results from a Phase 2b study of zunsemetinib, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis.

November 13, 2023
·
6 min read
Business

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Akero Therapeutics, Inc. reported third quarter financial results for the period ending September 30, 2023 and provided business updates.

November 13, 2023
·
9 min read
Business

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Milestone Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2023, and provided a clinical and corporate update.

November 13, 2023
·
13 min read
Business

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

BioLineRx Ltd., a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20, 2023, before the U.S. markets open.

November 13, 2023
·
1 min read
Policy

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Ipsen and Medison Pharma are pleased to announce the Health Canada approval for Bylvay™ for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis, a progressive and life-threatening liver disease.

November 13, 2023
·
13 min read
Business

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the third quarter ended September 30, 2023.

November 13, 2023
·
10 min read
Business

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

CervoMed Inc., a clinical stage company focused on developing treatments for degenerative diseases of the brain, announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights.

November 13, 2023
·
14 min read
Antibe Reports Q2 2024 Interim Financial and Operating Results

Antibe Therapeutics Inc., a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.

November 13, 2023
·
5 min read
Business

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Enanta Pharmaceuticals, Inc. announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2023 after the U.S. market closes on November 20, 2023.

November 13, 2023
·
1 min read
Business

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Abeona Therapeutics Inc. reported financial results for the third quarter of 2023 and provided corporate updates.

November 13, 2023
·
9 min read